Antiphospholipid antibodies in young Indian patients with stroke

Mishra, Mahendra Narain; Rohatgi, Shalesh

doi:10.4103/0022-3859.57387

Cited by 11 publications

(10 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both ACL and LA were positive in 6 (15%), and ACL and /or LA were positive in 11 (27.5%). Almost similar results were found by Mishra et al in India; ACL was positive in 6/28 (21.5%) patients, LA in 10/51 (19.6%), 2 had both, and 4 (29.4%) had ACL and/or LA (13). (Table 5).…”

Section: Discussionsupporting

confidence: 84%

Antiphospholipid antibodies in forty young patients with stroke

Khalissi¹,

Abass²,

Nabat³

2015

J. Fac. Med Baghdad

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 84%

Antiphospholipid antibodies in forty young patients with stroke

Khalissi¹,

Abass²,

Nabat³

2015

J. Fac. Med Baghdad

View full text Add to dashboard Cite

“…summarises the characteristics of the included studies. Subgroup analysis aiming at estimating whether aPL-positive young individuals have a greater risk for CVE when compared with individuals without aPL was possible in 15 studies 4 9 12–15 17 18 22 24 31 33 37 47 54…”

Section: Resultsmentioning

confidence: 99%

“…However, robust scientific data from large controlled population studies to support this statement are still lacking. An important limitation to our analysis is that adequate controls groups, crucial for the calculation of risk estimation, were available for only a few studies 4 9 12–15 17 18 22 24 31 33 37 47 54. Moreover, among these, the results of studies with less than 30 patients produced quantified OR with wide CIs and poor test accuracy as expected 58.…”

Section: Discussionmentioning

confidence: 99%

The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review

et al. 2014

View full text Add to dashboard Cite

Background Around 10% of all thrombotic cerebrovascular events (CVE) occur in young population and in a large proportion of those the trigger remains undetermined. Antiphospholipid antibodies (aPL) are recognised risk factors for ischaemic stroke and recurrent thrombotic events; however, the frequency of aPL in young people with CVE is still an unresolved issue. Objectives To estimate the frequency of aPL in young adults with CVE and to determine whether aPL-positive young individuals are at greater risk of CVE when compared with individuals without aPL by systematically reviewing the literature. Methods Medline reports published between 1970 and 2013 investigating the presence of aPL in young patients (<50 years old) with CVE were included. The median frequency for positive aPL, including lupus anticoagulant, anticardiolipin antibodies (aCL) and antibodies against β2Glycoprotein I (anti-β2GPI), was calculated for stroke and transient ischaemic attacks. Findings This systematic review is based on available data from 5217 patients and controls from 43 studies analysing the frequency of aPL in young patients with CVE. The overall aPL frequency was estimated as 17.4% (range 5%-56%) for any CVE, 17.2% (range 2%-56%) for stroke and 11.7% (range 2%-45%) for transient ischaemic attack (TIA). The presence of aPL increased the risk for CVE by 5.48-fold (95% CI 4.42 to 6.79). Based on available data, the frequency of aPL in young patients with CVE can be estimated at 17%, rising up to 22% for aCL in patients with stroke. The presence of aPL seems to confer a fivefold higher risk for stroke or TIA when compared with controls. However, variability in test reproducibility and cut-off definition still represent an important methodological limitation for the current diagnostic testing for aPL. These observations should be confirmed by appropriately designed population studies.

show abstract

“…Whether or not the presence of lupus anticoagulant poses a greater risk than other antiphospholipid antibodies remains unclear. Consistent associations between young ischaemic stroke and the presence of lupus anticoagulant and anticardiolipin antibodies are seen [96–100, 102, 103], although there are conflicting reports regarding the significance of anticardiolipin antibodies in older stroke populations [104–106]. Interpretation is complicated by methodological differences and the use of different cut-off values with stronger associations observed at higher titre cutoffs.…”

Section: Antiphospholipid Antibody Syndromementioning

confidence: 99%

Epidemiology and Etiology of Young Stroke

Griffiths

Sturm

2011

Stroke Research and Treatment

112

115

View full text Add to dashboard Cite

Introduction. Stroke in people under 45 years of age is less frequent than in older populations but has a major impact on the individual and society. In this article we provide an overview of the epidemiology and etiology of young stroke. Methods. This paper is based on a review of population-based studies on stroke incidence that have included subgroup analyses for patients under 45 years of age, as well as smaller community-based studies and case-series specifically examining the incidence of stroke in the young. Trends are discussed along with the relative frequencies of various etiologies. Discussion. Stroke in the young requires a different approach to investigation and management than stroke in the elderly given differences in the relative frequencies of possible underlying causes. It remains the case, however, that atherosclerosis contributes to a large proportion of stroke in young patients, thus, conventional risk factors must be targeted aggressively.

show abstract

Antiphospholipid antibodies in young Indian patients with stroke

Abstract: APL, positive family history and smoking were significantly associated with stroke in the young. We advocate screening for APL in all young patients with stroke.

Cited by 11 publications

References 13 publications

Antiphospholipid antibodies in forty young patients with stroke

Antiphospholipid antibodies in forty young patients with stroke

The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review

Epidemiology and Etiology of Young Stroke

Contact Info

Product

Resources

About